Gilead pays $21bn for Immunomedics ahead of breast cancer trial readoutGilead has made another big oncology acquisition, paying $21 billion for US biotech Immunomedics and its potential cancer Share XGilead pays $21bn for Immunomedics ahead of breast cancer trial readouthttps://pharmaphorum.com/news/gilead-pays-21bn-for-immunomedics-ahead-of-breast-cancer-trial-readout/
AstraZeneca inks $6bn cancer drug deal with Daiichi SankyoAstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, Share XAstraZeneca inks $6bn cancer drug deal with Daiichi Sankyohttps://pharmaphorum.com/news/astrazeneca-inks-6bn-cancer-drug-deal-with-daiichi-sankyo/
After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancersWith an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now Share XASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancershttps://pharmaphorum.com/news/asco-2020-astrazeneca-enhertu-cancer/
AZ/Daiichi’s Enhertu gains second ‘breakthrough’ tag in space of a weekThe FDA has said AstraZeneca and Daiichi Sankyo’s Enhertu could be a breakthrough in a potential new lung cancer niche, the second time in the Share XAZ/Daiichi’s Enhertu gains second ‘breakthrough’ tag in space of a weekhttps://pharmaphorum.com/news/azs-enhertu-gains-second-breakthrough-tag-in-space-of-a-week/
Daiichi Sankyo: pharma needs to become NHS ‘experts’If pharma wants to help the NHS improve outcomes, it needs to do so through a true partnership Share XDaiichi Sankyo: pharma needs to become NHS ‘experts’https://pharmaphorum.com/views-analysis-market-access/daiichi-sankyo-pharma-needs-to-become-nhs-experts/
Current pharma model “not sustainable” during COVID-19, says Daiichi’s UK leadAt eyeforpharma Daiichi Sankyo’s Manuel Reiberg spoke about why the industry should look to make drugs more affordable Share XCurrent pharma model “not sustainable” during COVID-19, says Daiichi’s UK leadhttps://pharmaphorum.com/news/current-pharma-model-not-sustainable-during-covid-19-says-daiichis-uk-lead/
Antibody-drug conjugates on the marchOne of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal Share XAntibody-drug conjugates on the marchhttps://pharmaphorum.com/views-analysis-oncology/antibody-drug-conjugates-on-the-march/
FDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filingThe FDA has approved an advanced breast cancer drug from AstraZeneca and Daiichi Sankyo in super-quick time. The Share XFDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filinghttps://pharmaphorum.com/news/fda-hastily-approves-daiichi-sankyo-azs-cancer-drug/
